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Abstract
Mitral regurgitation (MR) is a prominent cardiac disease affecting more than two
million people in the United States alone. In order for patients to receive proper therapy,
regurgitant volume must first be quantified. As there are an array of methods to do so, the
proximal isovelocity surface area (PISA) method continues to be the most accurate and
clinically used method. However, there are some difficulties obtaining the necessary
measurements need for this when performing transthoracic echocardiography. This study
aims to evaluate and present techniques that may be used to more accurately quantify
regurgitation through ex vivo testing and computational fluid dynamic simulations. Both
a steady and pulsatile flow system were created to test clinical applications used to
quantify MR using the PISA method. A total of six computational fluid dynamic cases
were then studied; three native mitral valves effected by MR as well as three valves
enacting to have MitraClip implantation, both sets of having a MR grade of mild,
moderate, and severe. All cases were effected by an eccentric ellipse orifice(s). Flow rate
was evaluated in each case, comparing actual flow rate to calculated flow rate, which was
found implementing the modified hemielliptic PISA model. The results of this study
implicate that clinical techniques used to quantify MR need an experienced technician, as
well as further developing current techniques used, which is best done through ex vivo
testing. The study further implied that severity may be significantly underestimated when
quantifying MR using the modified hemielliptic PISA method in the short view.
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Chapter One: Introduction
Mitral regurgitation (MR) is the most common valvular heart disease known,
having substantial prominence of morbidity and mortality in cardiac disease. As to
prevent left ventricular dysfunction, heart failure, and a lower quality of
life, MR warrants nearly 30,000 patients in the United States to undergo vital surgeries
annually.11; 13; 18 This prognosis is often due to functional impairment, anatomic integrity,
and insidious progression. When first evaluating MR, it is important to
examine patient etiology, mechanism, and pathology. MR must then be further evaluated
in order to classify the cause of regurgitation and quantify
severity, comparing this preliminary data to standard baseline measurements. Once
severity has been determined, a cardiac team is able to determine a course of treatment.
Although there currently are baseline standards used in clinical practice as to how
to quantify MR, the absence of a gold standard methodology remains to be a great
difficulty. It is prevalent to have quantification methods be accurate as possible; if not
regurgitant volume can be misconstrued, leading to erroneous course of treatment
recommendations and decisions.9 The treatment of mitral valve regurgitation can be
further advanced through clinical assessment methods, mathematical models
implemented, device development, patient-specific simulations, and ex vivo testing with
biologic simulators.
1

1.1 Mitral Valve Anatomy
In order for the mitral valve to perform optimally, there must be near perfect
function of the intricate relationship between the mitral leaflets, subvalvular structure,
mitral annulus, and the left ventricle. Any deformity can cause the valve to leak and for
regurgitation to occur. It is imperative to understand the anatomy of the mitral valve in
order to evaluate not only the mechanism of a healthy valve, but also the etiology of a
deformed valve to diagnosis regurgitation cause and severity.14 The mitral valve is
located in the left chamber of the heart between the left atrium and the left ventricle. Its
overall structure includes the mitral annulus, mitral leaflets, chordae tendineae, and
papillary muscles. The mitral annulus is bimodal in shape with the anterior and posterior
leaflets superiorly positioned, and the medial and lateral points positioned inferiorly.

1.1.1 Leaflets
There are two mitral valve leaflets that help to make up the valve, referred to as
the anterior and posterior leaflets. The anterior leaflet accounts for a much larger portion
of surface area than the posterior leaflet and is connected to the noncoronary and left
aortic cusps.18 The posterior leaflet is semicircular shaped with three scalloped segments
that are distinct through thin clefts between them. Both leaflets are attached to the
anterior and posterior commissure. The scalloped parts of the both leaflets are labeled 1
through 3; 1 being connected to the anterolateral portion, 2 being the middle scallop, and
3 being connected to the posteromedial portion. They are then referred to as A1, A2, A3
and P1, P2, P3.18
2

Figure 1.1.1: Mitral valve schematic view from atrial position. Anterior and
posterior leaflets show scallops with specific numbers for each, allowing for detailed
description of anatomy.18

1.1.2 Chordae Tendineae
The mitral chordae tendineae are fibrous structures made up of woven collagen
and elastin fibers, and extend from the mitral leaflets to attach to the papillary muscles.18
They serve to anchor the leaflets during systole and help to prevent prolapse of the
leaflets into the left atrium. There are three types of chordae; primary, secondary, and
tertiary. The primary chordae serves to maintain coaptation of the leaflets, extend to the
papillary muscle in a branch-like fashion, and attaching to the coaptation line. The
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secondary chordae serve to give support and length from the papillary muscle to the
leaflets. They attach at the middle of the leaflets and are not branch-like, but are much
thicker and longer than primary chordae.18 Tertiary chordae give structural support and
are attached to the leaflets from the basal myocardium.
1.1.3 Papillary Muscle
The two papillary muscles, the anterolateral and the posteromedial, connect the
chordae to the left ventricle. The papillary muscles cause contraction of the chordae and
leaflets during systole. There is an equal amount of chordae that extends from the
papillary muscles to the leaflets, with the anterolateral papillary muscle / chordae
attaching to medial half of the leaflets and the posteromedial muscle / chordae attaching
to the lateral half of the leaflets.18

Figure 1.1.2: Description of full mitral valve apparatus.14
4

1.2 Epidemiology & Pathophysiology of Mitral Valve
Determining etiology of the mitral valve is most commonly done through
transthoracic echocardiography (TTE).13 MR is originally classified as primary or
secondary. Primary MR is due to valvular dysfunction, whereas secondary (functional)
MR is due to abnormalities in the subvalvular structure and / or the left ventricle.9; 18 All
abnormalities of the mitral valve, left atrium, and left ventricle should be noted in detail
when being examined (i.e. size, location, extremity). As primary and secondary mitral
regurgitation are considered different diseases, it is imperative that different methods are
used for assessment, quantification, and course of treatment.13

1.2.1 Primary MR
Irregularities that occur in the leaflets are thickening, calcification, redundancy,
perforation, vegetations, and clefts. Left chamber dilation is an indicator that MR is
chronic and potentially severe.13 Primary MR is further determined based on Carpentier’s
classification of leaflet motion, as Type I (normal leaflet motion), Type II (excessive
motion), and Type III (restrictive motion).9 Prolapse is the most common type of primary
MR, caused by the dislocation / flail of the mitral leaflets during systole. Flail leaflet is
the inversion of the leaflet and distorting the natural concave shape of the leaflet and is
often a due to rupture of the primary chordae, giving loss of leaflet coaptation.18 Other
causes of primary MR are infection (endocarditis and leaflet perforations), inflammation
(thickening of leaflets and poor coaptation), rheumatic disease (leaflet scarring and
restricted leaflet motion), and radiation / drug induced (valvulitis and mitral stenosis).18
5

1.2.2 Secondary MR
Deformities causing functional MR include chordal rupture, thickening, fusion,
vegetations, and masses. A dilated left ventricle with isolated wall abnormalities can help
to identify severe secondary MR.13 Secondary MR occurs from ischemic and myopathic
left ventricle alteration, regardless if the valve is healthy or not, effecting the papillary
muscles and mitral leaflet coaptation.9; 18 Secondary MR is more common than primary
MR, as ischemic cardiovascular diseases are more common than valvular etiology.
Ischemic results from coronary artery disease and can also be caused by acute myocardial
ischemia.18

Figure 1.1.3: Anatomic description of Carpentier’s classification of mitral regurgitation.2
1.3 Assessment of Mitral Regurgitation
Mitral regurgitation is typically first detected in asymptomatic patients through a
systolic murmur found during an echocardiogram procedure.14 Regurgitation occurring in
6

the mitral valve is assessed through two types of echocardiograms; transesophageal
echocardiography (TEE) or TTE. Echocardiography is used to take images of the heart in
real-time, to help evaluate the structure of the etiology, physiology, and
hemodynamics.13; 22 TEE procedures are performed by cardiologists and are often used
if the data found from a TTE exam, performed by a sonographer, is
ambiguous.13 Initially, it is important for the clinical team to note all abnormalities
found in detail in order to help determine and classify the type of MR present.16 Patients
showing signs of mild MR are recommended to have less frequent examinations, about
once every five years, where as patients showing signs of moderate to severe MR are
recommended to have an annual exam.14 MR may also be assessed through noncardiographic methods, such as computed tomography (CT), cardiovascular magnetic
resonance (CMR), and angiography, but TEE and TTE are shown as the most accurate
practices used.22 Once MR has been classified, further investigation is need to more
accurately quantify the level of severity. As there is not a single procedure for this, the
American Society of Echocardiography (ASE) recommends an integrated approach using
many parameters to do so.18 This consists of an experienced cardiac / clinical
team performing the suitable echocardiogram, and obtaining these images /
measurements to be further used in mathematical modalities used to accurately quantify
regurgitant volume.

1.3.1 Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging (CMR) is a non-invasive assessment method
used to take images of the heart in real-time, displaying cardiac dysfunction. This
7

can also be used as another option to help quantify regurgitation severity, as images taken
are able to depict regurgitant orifice area, regurgitant volume, regurgitant fraction,
and LV volume, indicating remodeling that has taken place.1; 7 These measurements have
shown to correspond with data from other methods, such as Doppler, but there are still
quite a few disadvantages. Some major limitations with CMR is the lack of accessibility,
cost of the procedure, inability to account for hemodynamics, and difficulty aligning the
image with the most narrow part of the vena contracta.7 Although this method can help to
quantify regurgitation, it should mainly be used as a back up method for patients where
TEE is not optimal, and where TTE data shows to be inconclusive.1; 22

1.3.2 Transesophageal Echocardiography
Transesophageal echocardiography is a type of echocardiogram that requires
patient sedation, as an ultrasonic transducer is inserted through the esophagus in order to
take images of the heart in real time.1 TEE is known for giving generally the best overall
assessment of mechanism abnormalities (I.e. leaflet prolapse / restriction) and the lesion
causing regurgitation (I.e. chordae tendineae rupture, papillary muscle rupture, leaflet
perforation, etc.).1; 22 Whether or not MR is acute or chronic, as well as the chambers
capacity to adjust for the regurgitant flow, is also evaluated.23 Severity quantification
methods are also able to be performed through data gathered from TEE, however there
are some limitations. As regurgitant jet size is affected by transducer pulse repetition
frequency (PRF) and the strength of the transducer signal, which may overestimate jet
size.23 Though somewhat faultless images and quantitative data is able to be taken
through TEE, it is often avoided if possible due to patient risks as it is somewhat an
8

invasive procedure.1; 23 TEE is best used as a second option if the data taken shows to be
inconclusive and as a method for planning surgical repair / replacement.16; 23

1.3.3 Transthoracic Echocardiography
Transthoracic echocardiography (TTE) is the most common assessment
approach when evaluating valvular regurgitation as it is a non-invasive procedure and
there are various techniques to do so. This is done by placing an ultrasonic transducer on
the abdomen / chest to capture images of the heart. A great advantage of TTE is that there
is no affect on the hemodynamics unlike TEE.1 This procedure is performed by a trained
sonographer. 2D echocardiography helps to evaluate valvular structure and the impact of
volume overload in the cardiac chambers in present time through a single slice / twodimensional image.23 3D echocardiography is able to give a more complex image of the
mitral valve apparatus through the perspective of the left atrium (LA and left ventricle
(LV).7 Anatomic and functional abnormalities are also evaluated through this type of
echocardiogram. An advantage of a 3D echocardiograms is the ability to not rely on
geometric postulations when measuring the regurgitant orifice area, which is needed in a
2D echocardiogram.7 Doppler echocardiography is another type of echocardiogram
that uses high frequency ultrasonography to assess regurgitant severity. This is best used
to examine blood flow and has various indexes to do so; Pulsed Wave Doppler,
Continuous Wave Doppler, and Color Doppler.23 With the use of these three implications
and further analytical methods, valvular regurgitation is able to be quantified.

9

1.3.3.1 Pulsed Doppler
Pulsed Wave Doppler (PWD) is an index used when conducting a TTE
echocardiogram. Recordings of the velocity time integral (VTI) are used along with valve
measurements in order to obtain the flow rate and stroke volume at the mitral annulus.7; 23
This technique is also used to estimate the function of the LV in diastole during this
time by looking at the tracings of the mitral leaflets. When severe MR is present, mitral
inflow shows to have early filling due to an increase of flow across the valve during
diastole.23 This technique is best used as a qualitative indicator detecting variations in
blood flow during regurgitation, as well as accompanying other techniques and
quantification measures taken.22

1.3.3.2 Continuous Wave Doppler
Continuous Wave Doppler (CWD) best displays peak velocity of the MR jet,
showing high pressure gradient of the LV/LV during systole, as well as timing of
regurgitation.9; 22 Signal density is a useful indicator of MR severity and correlates with
angiographic standards, with a dense signal suggesting severe MR and a faint signal
suggesting mild MR.7; 18; 23 CWD can also gauge severity by pulmonary hypertension,
volume overload in the cardiac chambers, and intensity of the signal regarding the MR
jet.7; 16 This method should also be used with other index techniques as the pattern and
size / shape of the jet can differ considerably, based on the machine that is being used,
settings applied, and the alignment of the transducer in regards to the regurgitant jet.16 In
eccentric MR cases, this proves to be somewhat difficult to record the full envelop of
CWD, due to jet eccentricity and transducer placement.9
10

1.3.3.3 Color Doppler
Color Doppler (CD) is the most common clinical technique used, displaying the
spatial distribution of velocities within the image plane that is being captured.7; 22; 23 The
direction and shape of the jet shown are beneficial in mechanism diagnostics, as an
eccentric jet signifies pathologic regurgitation.16 There is broad assumption that as
the size of the jet increases, as well as the regurgitant volume into the LA, the level of
severity also increases. However, this can also widely differ due to hemodynamics,
ultrasonic machine / settings used, and operator technique.9
Though CD is considered best technique when detecting MR and its severity, a more
cohesive approach is needed when attempting to quantify regurgitation severity
accurately. Through Color Doppler three principle elements are able to be obtained; the
origin of the regurgitant jet and the width, spatial orientation of regurgitant jet area, and
the flow convergence through the regurgitant orifice.16; 22; 23 It has been indicated in many
studies that the measurements taken from these images, and that are further implemented
in analytical methods, is the most accurate way to assess MR severity.22; 23

1.4 Quantification of Mitral Regurgitation
1.4.1 Regurgitant Jet Area
Assessing the regurgitant jet area is one approach that can be used
to help determine MR severity. As a regurgitant jet indicates that MR is present, the area
greatly depends on the mechanism of MR, which can often result in inaccurate
measurements.7; 23 This method is only relevant when evaluating central jets, as eccentric
11

jets will be severely underestimated due to the Coandal effect and being influenced by the
LA wall.16; 23 This method is also flawed by not accounting for hemodynamics, as well as
being largely affected by machine settings.16 It is imperative that this method is used
along with examining the vena contracta and flow convergence.22

1.4.2 Vena Contracta
Measurement of the vena contracta width (VCW) is taken at the smallest high
velocity sector of the jet, which is located downstream or at the regurgitant orifice.7; 19; 23
This The width is measured in the long-axis plane perpendicular to the commissure, but
can vary during systole or under the affects of other hemodynamics present.7 VCW is
typically smaller than the anatomic regurgitant orifice area due to boundary
affects, representing the effective regurgitant orifice area (EROA). Unlike
regurgitant orifice area, VCW is not as affected by machine parameters as it is
independent of the flow rate, driving pressure, and has a high velocity.16; 23 This method
is also able to evaluate concentric and eccentric, however, there is some assumption that
the regurgitant orifice is circular in shape.9 As it is also unclear how to evaluate multiple
jets present, as well as underestimating severity when the orifice is elliptic in shape, the
vena contracta method should be used alongside with the flow convergence method to
better assessing these cases.

12

1.4.3 Flow Convergence ; Proximal Isovelocity Surface Area
Evaluating the proximal isovelocity surface area (PISA), also known as flow
convergence, has proven to be the preeminent approach to quantify MR severity. This
method is based on the continuity equation and principle that as blood flows through the
orifice the velocity increases, forming hemispheric shells of increasing velocity, with a
decreasing surface area.16; 23 Color Doppler imaging identifies the flow convergence near
the regurgitant orifice area (shell). The radius of the hemispheric shell is measured,
allowing for peak flow rate and EROA to be determined, assuming that the PISA radius
is occurring simultaneously at peak regurgitant flow.7 Clinicians are instructed to
measure PISA radius of the hemispheric shell for these calculations, but there is
minimal specifications on how to do so throughout present literature and guidelines.12 As
the radius is measured to the aliasing velocity point of the color Doppler image (known
as the PISA radius), this can be highly dependent on machine parameters implemented.12
The placement of the transducer to capture the orthogonal images can be somewhat
difficult, as it needs to align with the regurgitant jet / orifice, showing that this method
is most accurate for concentric jets.7; 16; 23 However, the majority of orifices present in
MR are dynamic and not circular in shape, but rather more of an ellipse.7; 9 This can
greatly affect the PISA calculation by showing errors in the formula,
underestimating flow rate and EROA.7; 16; 22 There is also an assumption that velocity
distribution is symmetrically hemispheric, which is unlikely to hold true when evaluating
orifices that are ellipse in shape, eccentric jets, and multiple jets present.9 Although there
is a hemielliptic formula that may be used, this mainly addresses the orifice structure. The
images needed for this method have also proved to be extremely difficult to obtain,
13

as 3orthogonal measurements are needed. A modified version of the hemielliptic method
has been proposed and shows substantial promise as to how these measurements may be
more effectively taken in a clinical setting.6

Figure 1.4.1: Proximal isovelocity surface area depiction of PISA shell. Measurement of
the radius should be taken at the aliasing velocity; if not, estimation of flow rate will be
inaccurate.16

1.5 Treatment of Mitral Valve
Surgical intervention is often needed in patients with moderate to severe MR in
order to provide longevity and a better quality of life. Once an echocardiogram has been
14

performed, and MR severity has been determined, a cardiac surgeon will often perform a
TEE (if one has not been done already) to determine whether or not the valve should be
repaired or replaced.14 Through TEE precise delineation of the valve apparatus will be
evaluated prior to surgery, as well as overall hemodynamics, and potential surgical
procedures will be discussed amongst the surgeon and cardiologist, before presenting the
best options to the patient.14 Although surgical repair is often needed for those suffering
from severe MR, the desired method is to implement a repair technique of the valve, as it
is a much less invasive procedure than that of valve replacement.

1.5.1 Surgical Valve Replacement
Mitral valve replacement is needed when the valve cannot be repaired. This is
done by removing the innate valve, replacing it with a mechanical valve or a valve made
from human, cow, or pig tissue. However, mechanical valves are often chosen as
biological tissue valves degenerate as time goes on and will eventually need intervention
of a second surgery.14 MV replacement can be executed through a surgical procedure or
through new technology using transcatheter mitral valve replacement (TMVR). Once a
mechanical valve is inserted, patients will need to take anticoagulation medications
for the remainder of their life. It is prominent during the replacement process that chordae
is preserved as much as possible. There are currently 8 TMVR devices in preliminary
trials, majority of which having a transseptal approach to implementation.5 Though
replacement of the valve post-operation has a high success rate, some difficulties due to
this are long recovery times and medical complications that may occur during operation
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time. For these reasons, repair of the valve is most sought after, especially with new
technologies that are being able to do so.

1.5.2 Surgical Valve Repair
MV repair is the most sought-after option in addressing MR, as a minimally
invasive procedure that is able to repair valve leaflets, chords, or by removing misplaced
tissue. Repair is done through using edge-to-edge leaflet coaptation with a clip securing
anterior and posterior leaflets where the regurgitant orifice is located.13 Advantages of
repair is evasion of long-term anticoagulation’s, minimal recovery time, low risk of
medical complications, and, most importantly, preservation of the continuity between the
mitral annulus and the papillary muscle. This preservation is crucial as it correlates
with the decrease in operation mortality.14 Through transcatheter mitral valve repair, the
technique of implementing a device is being used by cardiologists as a means of
restoration for those with moderate to severe MR. The MitraClip device is currently the
only FDA approved device for repair via implantation through a transcatheter approach.
Currently, implementing a MitraClip in patients affected by primary MR is not
often executed, as viability and surgeon experience need to be accounted for.13
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Figure 1.5.1: Mitral valve before and after MitraClip implantation. Double orifice present
post-operation.2

1.5.2.1 MitraClip Implantation
The MitraClip is a new technology and has quickly become the gold standard
treatment option for those affected by MR. It is minimally invasive procedure, able to be
placed in the heart via transcatheter. The clip system is made up of two parts; a steerable
guide catheter and the clip delivery system. The clip itself is polyester-covered
cobalt chromium with two are “arm” that are controlled by the delivery system during
implantation. The inner portion of the clip are two grippers that help to secure the leaflets
as the clip closes. The tissue is then firmly secured through the arms of the clip and
grippers. Once there is reduction in backflow, showing minimal regurgitation, the clip is
locked into place.2 The device essentially uses the edge-to-edge principle. This is a
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surgical technique that was introduced by Ottavio Alfieri in the 1990’s, suturing the
leaflets at the site of regurgitation. A centrally applied suture resulted in a double orifice
repair, where as a suture applied to either side of the orifice resulted in one opening,
referred to as a commissural repair.2 MitraClip procedure has proven effective
in reducing regurgitant volume and improving clinical symptoms. At present, those with
secondary MR are predominantly selected for MitraClip procedure. Though it has also
been used for cases regarding primary MR, as it is still a new technology, the effects and
outcomes due to clipping may vary based on patient-specific heart anatomy and
etiology.17

Figure 1.5.2: MitraClip device system.2
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1.6 Simulated Cardiovascular Biomechanics
With many clinical applications available to quantify MR severity,
a significant flaw is the absence of consistent technical procedures and a gold standard
used to do so.11 As the ASE has recommended that the most accurate way to quantify is
through the PISA method, machine parameters administered and clinician techniques can
affect severity quantification by both under and over estimation.11 Through the use of
finite element (FE), fluid-structure interaction (FSI), and computational fluid dynamics
(CFD), various simulations have been performed emulating echocardiography and
evaluating MR through models constructed from patient-specific CT data. Though some
studies have shown to be inconclusive, the development of CFD aims to prove its
importance in medical headway. The ability to use patient-specific data can be used in
numerous ways; simulating plausible treatment methods, evaluating efficacy, and
predicting possible complications.3

1.7 Cardiac Simulators and Ex vivo Testing
As clinical techniques, analytical models, medical devices, and computational
methods continue to develop, it is essential that these new practices be assessed and
perfected before executing in a clinical setting. In the past, cardiologists and cardiac
surgeons have learned new device implantation through low-fidelity simulations, giving
little to no visual control and unfeasible physiologic conditions.10 As medical devices and
surgical procedures continued to evolve, so did the need for a simulator emulating
biological conditions. There are currently a few simulators that use biological organs, in
order to emulate anatomic and hemodynamic cardiac circumstances. These simulators
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allow for practice to be done in the Cartesian X,Y and Z planes, as well as being able to
monitor and regulate hemodynamic conditions in a controlled environment.10 Ex vivo
testing with the use of biological simulators proven to have a vast impact on clinical
practices through validating, optimizing, and designing new techniques used.15; 21 Most
simulators use porcine myocardium as human analog because of similarity in anatomy,
size, and tissue microstructure.8

Figure 1.7.1: Representation of left-heart simulator while undergoing artificial chordae
replacement.10
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1.8 Research Aims
As there is no single or correct answer for a pathway to therapy, it is crucial to
have an experienced and multidisciplinary cardiac team. It is currently recommended that
those with chronic primary MR undergo surgery, however, MitraClip is now being
considered as a plausible option. It has shown to be safe and effective in reducing
regurgitation, LV remodeling, and clinical symptoms. This therapy needs to be further
explored as it may be the leading choice for the aging population affected by primary
MR.13; 20 However, studies have shown that in modern clinical practice less than half of
patients that have moderate to severe MR receive adequate treatment, mainly due to not
being properly addressed by the treating physician.20 This goes to show the importance of
recognizing MR severity accurately and need to optimize practices, as well as modify
current guidelines.
As previously shown, there are an array of difficulties and limitations in current
practices seeking to quantify severity as accurately as possible. This paper aims to give a
comprehensive engineering analysis of quantification using the modified-hemielliptic
PISA method, impact of the MitraClip implementation, ex vivo testing methods, and
further development of a biological simulator. More specifically, through the use of
computational fluid dynamics, the modified-hemiellptic PISA method will be used to
quantify severity in native valves of mild, moderate, and severe MR, as well as valves
with MitraClip implantation showing mild, moderate, and severe. These cases are
classified as primary MR with orifices that are ellipse in shape and have eccentric
regurgitant jets. This practice will then be attempted through ex vivo testing, as well as
originating the first full cardiac simulator. Comparing the regurgitant flow rates found
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using the modified PISA method to the actual flow rates found in the computational
simulations will display the relevance of using CFD in a clinical setting. Furthermore, it
will give insight as to how clinical techniques in quantifying MR may be improved.
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Chapter Two: Methods
2.1 Ex vivo Testing
Two experimental testing systems were designed to perform ex vivo testing; a
steady flow and a pulsatile flow system. Both flow systems had
advantages and disadvantages throughout testing, however both proved to be highly
beneficial in intracardiac visualization, displaying the importance of hemodynamics,
and significance of clinical practice assessment. Each simulator was used to implement
doppler echocardiography procedures on porcine heart subjects and gather necessary data
to evaluate quantification of MR severity. A working solution of 37% glycerin in saline
was used as the properties emulate that of blood. Prior to each testing trial with both
simulators, flow meter calibration was performed.

2.1.1 Steady Flow Design
Experimental testing was first executed using a steady flow system. As a means of
preliminary testing, this methodology allowed for evaluation of pitfalls within a simple
flow system connected to a porcine heart, as well as indicating potential pitfalls within a
pulsatile flow system. This system was affixed to the left side of the heart only, through
the aorta and pulmonary veins, and was done so using tubing adapters and
clamps. Connection of the pump was also implemented at the left ventricle with an array
of 3D printed adapters that were designed, CAD modeled, and printed “in house" by
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a Formlabs 2 resin printer, to ensure a secure connection with minimal leakage. The flow
system had a control valve, Transonic flow meter, and was driven by an Iwaki Magnet
Pump. Once all connections were in place and secured, the working fluid was
applied. As testing trials progressed, many techniques were investigated to find optimal
results.

Figure 2.1.1.1: Schematic of Steady Flow System.

Figure 2.1.1.2: Steady Flow System design.
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2.1.2 Pulsatile Flow Design
A steady flow system is adequate for initial testing methods, however the need
for a pulsatile flow system in order to initiate physiologic attributes is of significance.
Furthermore, the need for a full cardiac simulator, as opposed to a sole left heart
simulator, is necessary in order to give full hemodynamic properties throughout the
cardiac cycle. As previously only left heart simulators have been created and used in
cardiac ex vivo testing, these systems were evaluated and assessed prior to designing a
full cardiac simulator.

Figure 2.1.2.1: Schematic of Full Cardiac Simulator (i.e. Pulsatile Flow System).
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Figure 2.1.2.2: Full Cardiac Simulator design.

2.1.3 Full Cardiac Simulator Construction
Compliance and reservoir chambers needed for the system were designed
after BDC Laboratories models that are currently sold on the market. CAD models based
on these designs were created in SolidWorks, with some modifications in measurements
to fit other necessary supporting parts. Large pieces of acrylic were obtained from
Colorado Plastics Company and modified / cut by a HAAS Super Mini Mill computer
numerical control (CNC) machine. Once the chambers were assembled, they were fit to
the standard ¾ inch tubing used throughout the system. As shown in the
schematic, each compliance chamber was connected to a control valve, reservoir,
and pressure transducers at the valves. Both pressure at the valves and flow rate were
monitored throughout testing. All pieces were affixed by appropriate tubing adapters and
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clamps ensuring minimal leakage. The compliance chambers were connected to the heart
at the superior vena cava and the aorta (with a flow meter inserted between this
connection), and with the reservoirs connected to the pulmonary artery and pulmonary
veins. BDC Laboratories PD-1100 Pulsatile Pump System was attached to the heart at the
apex, with insertion into both the right and left ventricle. This was done by an array of 3D
printed cannulas that were tested for optimal connection. As the pulsatile pump pistons
run optimally with water, a feedback loop was implemented to ensure minimal working
solution to interfere with the pump, as well as having a control outlet for air trapped
within the system. Once the system was attached to the heart and all clamps were
secured, the working fluid was applied. The system was run a few times prior to testing to
inspect for any leakage or air within the system present.

2.2 Experimental Subjects
As porcine hearts remain to be an appropriate human analog, they were chosen to
be used as the experimental subjects throughout this study. The first set
of subjects were obtained through Biology Products, specializing in specimens used for
academic purposes. The second set of subjects were obtained through a local
slaughterhouse. As the first set of hearts were withdrawn from the pericardium upon
receiving them, the second set of hearts were attached to the lungs and pericardium. This
was removed carefully, ensuring to leave as much of the superior vena
cava, aorta, pulmonary artery, and pulmonary veins as possible to assure secure
attachment to the flow systems. Measurements of heart connection points were often
taken, however the size showed to vary minimally. Prior to testing, all hearts were
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thoroughly rinsed of blood and cleaned of unnecessary remaining pieces. Each test heart
was then manipulated in various ways throughout the testing trials to emulate MR
pathophysiology. This was done first by removing the aortic valve entirely, pressurizing
the heart through the aorta, and inflating the mitral leaflets. Cuts were then made on the
leaflets as close to the commissure as possible, either on the anterior leaflet or posterior
leaflet. The removal of some chordae tendineae was also occasionally applied. Once the
valve was modified, the heart was inspected for any present cuts, placing sutures on any
visible to mitigate leakage.

2.3 Doppler Echocardiography Techniques
There are currently parameter guidelines implemented throughout clinical
practice to obtain the necessary images to quantify MR through PISA, however, machine
settings and clinician techniques may vary, causing measurements to be less
accurate. While these guidelines have been proven to be pertinent to concentric jets
with an orifice being of circular shape, they remain to be scrutinized when it comes to
eccentric jets and orifices that are elliptic or organic in shape.22 The shape of the
regurgitant orifice, affecting the shape of the regurgitant jet and therefore vital transducer
alignment, is what remains to complicate accuracy of all PISA calculations.

2.3.1 Mitral Regurgitation Parameters / MR TTE methods
Transthoracic echocardiogram was performed on heart subjects using a Philips
iE33 Ultrasound Machine and x-51 transducer. Methodology and guidelines proven
effective throughout clinical practices of MR quantification were executed. A certain
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series of images for necessary measurements need to be taken for MR quantification. The
apical four chamber view is used for an optimal visual of all four heart chambers, with
the parasternal long and short axis view used for more complex pathophysiological
affected valves, namely when eccentric jets are present.9 Proper alignment of the
transducer with the present jet is essential, as inaccurate data can be acquired if not,
leading to inaccurate severity diagnosis.23
Certain technical parameters need to be accounted for on regards
to optimal acquisition, in order to enhance visualization of the MR orifice area by
the PISA shell. These settings were first checked making sure color Doppler variance
mapping was shut off prior to testing.19; 23 The mitral regurgitant jet is often referred to as
the mosaic color protruding from the mitral valve into LA during systole. Images are
taken throughout systole to examine the proximal flow convergence region (PFCR)
where the isovelocity shell is seen, with the most accurate PISA measurement typically
taken mid-systole. As radius is measured to the aliasing velocity (I.e. the blue-red
interface) and is affected by the compilation of these parameters, it is crucial that
optimization is be accurate as possible. Color gain was considered lowered as random
color noise can cause inaccurate visualization of the jet. The Nyquist limit defines
frequency and is considered to be the most important factor when taking measurements
for PISA, as it most directly affects the resolution and integrity of the PISA shell.16
This was considered within the range of 40-60 cm/second.9; 16; 19 Within this range has
shown to give the optimal imaging of the PISA shell, however it may still be somewhat
unclear as to where aliasing velocity is and where radial measurement should be taken. In
order to account for this, a practice of baseline shifting is applied. This is done by shifting
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the color scale baseline 30-40 cm/second in the direction of the regurgitant jet.9; 16; 19; 22
After necessary images were taken for PISA measurements in the orthogonal views,
continuous wave Doppler measurements were taken to obtain the peak velocity of
MR. Referred to as “color compare / suppress” color Doppler was switched on and off
with CW Doppler to take a series of images. This method is known to improve accuracy
in identifying both PISA shell and peak velocity.19 As peak velocity is often found
around 5 m/second, this was used as a gauge.19; 22
Ultrasonic gel was applied to the transducer prior to placement on the heart.
The mitral valve was located using 2D Doppler setting, as this is the best image depicting
the anatomy. The color Doppler and CW Doppler techniques were then
implemented. Throughout testing, the transducer was placed on various parts of the heart,
in means of obtaining the most accurate measurement with the jet (s) present within the
test subject. As heart subjects were manipulated in various ways emulating MR,
transducer placement aimed to align with the present jets as accurately as
possible. Various approaches were used to obtain this (see appendix), however, the
typical apical and parasternal views were utilized the most. This procedure was practiced
with both the steady and pulsatile (full cardiac simulator) flow systems. The technical
acquisition techniques described for MR quantification via TTE above were used
throughout experimental testing.
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2.4 Computational Fluid Dynamics
2.4.1 Model
Multiple computational models of the left heart (I.e. the left atrium, mitral valve,
and ventricle) were created to test MR simulations. The left atrium and ventricle were
based on de-identified patient-specific CTA data acquired from the University of Utah.
The mitral valve geometries were created based on a previous research study (et
al. Delgado, V., Tops, L. F., Schuijf, J. D.). In this study patients underwent a multisplice spiral computed tomography (MSCT) scanner, acquiring 64-slices, as well as an
electrocardiogram simultaneously recording data throughout multiple cardiac cycles for
appropriate reconstruction.4 Patients assessed in this study had heart failure and
were affected by moderate to severe MR. Data showed asymmetric deformations of the
mitral valve, especially in regard to the angles of the posterior leaflet values at the central
and posteromedial levels, resulting in notably higher differences of MV tenting height at
these levels.4 A “base” mitral valve CAD model using SolidWorks was created based on
this data with the annulus of the valve constructed to fit the previously obtained LA and
LV model used. This valve was further modified to emulate mitral regurgitant valves and
mitral regurgitant valves with MitraClip implementation. As the shape of
the commissure is a product of the tenting heights in place, insertion of elliptical
orifices at the commissure showed to be in applicable position that would display
eccentric regurgitant jets. The bottom of the left ventricle was removed, as this would be
the flow inlet.
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Table 2.4.1.1: Details of Native Mitral Valve orifices created.
Case

Short Axis
Radius, mm

Long Axis
Radius, mm

Calculated Orifice
Area, mm2

Actual Orifice
Area, mm2

NMV Mild

0.85

1.69

4.51

5.00

NMV
Moderate

1.29

2.59

10.52

11.72

NMV

1.78

3.55

19.80

22.13

Severe

2.4.1.1 Native Mitral Regurgitation Valve
A total of three cases of native mitral regurgitant valves were modeled. This was
done by cutting an ellipse orifice through the model at the center of the
commissure. Three orifice sizes were chosen to emulate mild, moderate, and severe
regurgitation. These models were then further tested through the simulation process.

Table 2.4.1.2: Details of MitraClip Mitral Valve orifices created.
Case

Short Axis
Radius, mm

Long Axis
Radius, mm

Calculated Orifice
Area Total, mm2

Actual Orifice Area
Total, mm2

MCMV
Mild
MCMV
Moderate
MCMV
Severe

3.39

6.77

4.70

5.09

4.38

8.75

12.88

14.51

5.18

10.35

21.74

24.95

2.4.1.2 MitraClip Implantation in Mitral Regurgitation Valve
The native mitral regurgitant valves with ellipse orifices corresponding to mild,
moderate, and severe MR were further modified by mimicking MitraClip implantation.
This was done by using the dimension of the width of the MitraClip, 5mm, a method also
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previously used in CFD / FSI studies.3 With the clip in place at the center of the previous
regurgitant orifice, each valve then had two smaller ellipse orifices remaining on both
sides of the clip.

2.4.2 Mesh
After six complete models were assembled (i.e. atrium, ventricle, and respective
valve) and displayed no gaps within geometry connection points, meshes were created
based on each model. This was done using the fluid focalized software Pointwise. Four
meshes were initially made of the native mild MVR model in order to assess mesh
quality. The element size of the valve geometry remained the same throughout the four
complete model meshes, however the element size of the left atrium and ventricle
were modified, evaluating different element sizes. Meshing of different element sizes and
further testing these models through the fluid simulation allows for the comparison of
convergence. The mesh that contains the least amount of elements and fully converges is
then chosen as this certifies optimal computational run time while supporting a highfidelity simulation. The mesh element size of the LA / LV referred to as Medium Fine
was chosen to be used throughout the 6 models. Prior to fluid simulation testing,
each mesh quality and accuracy was assessed, validating that no errors were present.

2.4.3 ANSYS Fluent Simulation
Fluid simulations were run by ANSYS Fluent software. As shown during
the mesh convergence verification process, simulations showed full convergence
after 400 iterations. Prior to running the fluid simulation, all boundary
33

conditions parameters were evaluated and set. These boundary conditions were applied to
all six model simulations. Once all fluid simulations were completed, all data was
exported to be further processed.

2.4.4 Simulated Echocardiography
As each CAD model created had an ellipse orifice, the hemielliptic PISA model
would be implemented to quantify for regurgitant severity. The original hemielliptic
PISA model is calculated by obtaining three measurements through 3 orthogonal views;
1) the radius in the lateral view of the long-axis, 2) the radius in the lateral view of the
short-axis, 3) the radius vertical to the orifice plane.
However, due to clinical limitations of obtaining an accurate image for the
approach of the vertical radius over the orifice plane, a new modified hemielliptic model
has been developed. This is done by obtaining two radial measurements; 1) the radius
parallel to the long-axis of the ellipse orifice, and 2) the radius parallel to the short-axis of
the ellipse orifice. These measurements are able to be taken accurately in a clinical
setting in the apical view.
Using Tecplot post-processing software, the fluid model was able to be manipulated in
countless amounts of ways. Each of the necessary image were able to be obtained by
inserting a plane directly intersecting through all mid-points of each orifice, in order to
find the regurgitant jet. Further post-processing was conducted to emulate clinical factors
of the Doppler Color scale and Nyquist baseline shift method, in order to take accurate
measurements of the PISA shell present.
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2.5 Quantification of MR Severity; Modified-Hemielliptic PISA Method
PISA measurements are taken (in clinical examination by TTE) by shifting the
baseline color toward the direction of the MR jet in order to find a clear image of the
PISA shell at peak regurgitation. The radius is measured from the center of the orifice,
in the both the short-view and long-view, to the aliasing
velocity. Hemispheric PISA is calculated as
𝑃𝐼𝑆𝐴 = 2𝜋𝑟 ! ∗ 𝑉𝐴

Equation 1

2pi being the hemispheric area, r being the PISA radius, and VA being the aliasing
velocity. If the base of the PISA sphere is not a flat surface, then there is a need for
correction to account for wall constraint. An additional measurement is then taken of the
shell angle and the equation is multiplied by the angle ratio of the walls adjacent to the
orifice and 180 degrees.7
𝑃𝐼𝑆𝐴 = 2𝜋𝑟 ! ∗ 𝑉𝐴 ∗ (

#$%& %'()) &*+)(
,-.

)

Equation 2

As each CAD model created had an ellipse orifice,
the hemielliptic PISA model would be implemented to quantify for regurgitant severity.
The original hemielliptic PISA model is calculated by obtaining three measurements
through 3 orthogonal views; 1) the radius in the lateral view of the long-axis, 2) the
radius in the lateral view of the short-axis, 3) the radius vertical to the orifice plane.
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However, due to clinical limitations of obtaining an accurate image for the
approach of the vertical radius over the orifice plane, a new modified hemielliptic model
has been developed. This is done by obtaining two radial measurements; 1) the radius
parallel to the long-axis of the ellipse orifice, and 2) the radius parallel to the short-axis of
the ellipse orifice. These measurements are able to be taken accurately in a clinical
setting in the apical view. This modified hemielliptic model can then be calculated by

𝑃𝐼𝑆𝐴 = 2𝜋 [

/0 !.# 1/2 !.# 102 !.#
3

] ∗ 𝑉𝐴 ∗ ((𝑃𝐼𝑆𝐴 𝑆ℎ𝑒𝑙𝑙 𝐴𝑛𝑔𝑙𝑒)/180)

Equation 3

a being the radius of the short-axis of the orifice, b being the radius of the long-axis of the
orifice, c being the PISA radius measured in the short-view or long-view, and VA being
the aliasing velocity. Effective regurgitant orifice area (EROA) and regurgitant volume
(RVol) are then able to be calculated flow rate measurements, quantifying regurgitation.
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Chapter Three: Results
3.1 Experimental Testing
Notations were taken throughout experimental testing trials to evaluate techniques
used in ex vivo testing. This was done by continuously evaluating the techniques
implemented regarding the flow system, connection of the heart within the flow system,
heart anatomy, and ultrasound techniques to measure regurgitation.
Figure 3.1.4 displays the Steady Flow System built for the first half of
experimental testing, with Table 3.1.1 displaying the optimal techniques found regarding
this system. Figure 3.1.11 displays the Full Cardiac Simulator that was built for a
pulsatile flow, with Table 3.1.2 displaying the optimal techniques found regarding this
design. Testing notes throughout individual trials can be found in the appendix (as shown
in Table 5.2).
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Figure 3.1.1: Preparation of pig heart. Evaluation of present cuts prior to inserting
necessary sutures.

Figure 3.1.2: Mitral valve with large cuts made on A2 and P2. Suture put in place to
imitate MitraClip implantation.
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Figure 3.1.3: Fully prepared heart prior to attachment to the flow system.

Figure 3.1.4: Ex vivo Steady Flow System.
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Figure 3.1.5: Heart connected to Steady Flow System. Left atrium is unattached from
tubing of the system and propped up, ensuring that the LV and LA are continuously filled
with fluid, with no air trapped inside.
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Figure 3.1.6: Optimal positioning of the transducer on the apex of the heart. Removal of
the RV in the first image showed to be the most optimal ex vivo testing method when
taking necessary images / measurements for PISA.
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Table 3.1.1: Steady Flow System optimal experimental testing techniques.
Flow System

•
•

Secure connection needed of tubing to valves
Use of PIV particles is not necessary; causes unclear imaging

Heart Anatomy

•
•

Pressurize heart before cutting the mitral valve
Cut mitral valve close to the commissure on A2 and P2 for
regurgitation
Fill RV with water and insert cap
Remove RV entirely
Pulmonary veins do not need to be connected to tubing; ensure no air
is caught within the LV

•
•
•

Heart Connection

•
•

Ultrasound Techniques

(a) Aortic Cap

Find 2D image of anatomy prior to color Doppler
Shift Nyquist based on flow

(b) Apical Cannula 1

(d) Apical Cannula 3

(c) Apical Cannula 2

(e) Apical Cannula for RV / LV

Figure 3.1.7: CAD model designs of 3D printed cannulas used throughout ex vivo testing.
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Figure 3.1.8: CAD model of Compliance Chamber made for the Full Cardiac Simulator.
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Figure 3.1.9: CAD model of Reservoir made for the Full Cardiac Simulator.
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Figure 3.1.10: Test heart completely connected to the Full Cardiac Simulator at all six
junction points.

Figure 3.1.11: Ex vivo Pulsatile Flow System; Full Cardiac Simulator.
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Table 3.1.2: Full Cardiac Simulator optimal experimental testing techniques.
Flow System

•

Secure connection needed at all connection points ;
no air within the system

Heart Anatomy

•

Need to leave as much muscle at connection points
as possible
Pressurize heart before cutting the mitral valve
Cut mitral valve close to the commissure on A2
and P2 for regurgitation prior to connection
All connection points must be secure; minimal to
no leakage
Specialized cannula needed for apical connection
point
Find 2D image of anatomy prior to color Doppler
Shift Nyquist based on flow

•
•
Heart Connection

•
•

Ultrasound Techniques

•
•

Figure 3.1.12: Pressure measurements were monitored throughout testing at the superior
vena cava, pulmonary artery, aorta, and pulmonary veins via pressure transducers.
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Figure 3.1.13: DICOM ultrasound imaging. Color Doppler showing regurgitant jet in the
mitral valve in images 1 and 2 (top). Continuous Wave Doppler shows steady flow
withing the Steady Flow System in image 3 (bottom).

3.2 Computational Fluid Dynamics ; Simulation Contours
A total of six simulations were run; three for Native Mitral Valve MR regarding
mild, moderate and severe severity and three for MitraClip implantation Mitral Valve
regarding mild, moderate, and severe severity. All simulations were conducted under the
same conditions. The following contours show the present regurgitant jet and where the
PISA radius was measured regarding the case and view of the valve. Regarding each
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specific orifice of each case, two planes were created in the short-view and long-view,
aligned with the anatomic coordinates. This ensured that the measurements were taken in
the essential plane regarding the inflow at the bottom of the LV, as every orifice is ellipse
and eccentric.

Figure 3.2.1: CAD model of Native Mitral Valves, mild, moderate, and severe,
respectively.

Figure 3.2.2: CAD model of MitraClip Mitral Valves, mild, moderate, and severe,
respectively.
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Figure 3.2.3: CAD model of left heart; left atrium, mitral valve, and left ventricle.
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Figure 3.2.4: Meshed model of the full left heart model.

Table 3.2.1: Mesh element sizes assessed for optimal simulation convergence.
LV & LA
Mesh Size, mm

Mitral Valve
Mesh Size, mm

Element Size

Main

1.0

0.35

3,034,793

Fine

0.7

0.35

5,094,754

Medium fine

0.65

0.35

9,118,203

Super fine

0.5

0.35

13,075,301
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Table 3.2.2: Boundary Conditions applied in ANSYS fluid simulation.
Parameter
Fluent Launcher Settings
Solver

Value
3D; Double Precision;
Parallel Processing
Pressure-Based

Time

Steady

Viscous Model

K-epsilon (2eqn)

Fluid Density

1060 kg/m3

*Blood property

Fluid Viscosity

0.004kg/m-s

*Blood property

Pressure Inlet

16665.3 Pa

Pressure Outlet

666.6 Pa

Pressure Outlet

15998.7 Pa

*Applied at bottom of Left
Ventricle
*Applied at Pulmonary
Veins
*Applied at Aorta

Residual Convergence

1e-06

Solution Initialization

Hybrid

Number of Iterations

300
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Note

Figure 3.2.5: Image of left heart model post-processing. Short and long view of
regurgitant flow through the orifice, respectively.

Figure 3.2.6: Native Mitral Valve velocity magnitude contours in the short-view
displaying the regurgitant jet in the mild, moderate, and severe MR cases, respectively.
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Figure 3.2.7: MitraClip Mitral Valve velocity magnitude contours in the short-view
displaying the regurgitant jet in the mild, moderate, and severe MR cases, respectively, in
both the back orifice (top row) and front orifice (bottom row).

3.3 Quantification of Mitral Regurgitation ; Modified Hemielliptic PISA
Calculated flows were compared to actual flow rate values found in the simulation
by the sum found at the pulmonary veins. Measurements for modified PISA
quantification were taken from the velocity magnitude contours in both views. As shown
in Figure 3.3.1, the radial measurement of the PISA shell was taken from the most narrow
point of regurgitant flow to the aliasing velocity (red-blue color shift). The angle of the
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PISA shell (Figure 3.3.2) was measured from the full PISA shell shown, not only
considering 180 degrees.

Figure 3.3.1: Computational simulation PISA radius (r) measurement.

Figure 3.3.2: Computational simulation PISA shell angle measurement.
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Table 3.3.1: Displays computational simulation Native Mitral Valve data regarding
severity case. Regurgitant Orifice Flow Rate, Effective Regurgitant Orifice Area,
Regurgitant Orifice Flow Rate Total of short and long view data, Effective Regurgitant
Orifice Area Total of short and long view data, Actual Flow Rate, and respective
Percentage Errors of each compared to the Actual Flow Rate.
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Table 3.3.2: Displays computational simulation Mitral Clip Mitral Valve data regarding
severity case. Regurgitant Orifice Flow Rate, Effective Regurgitant Orifice Area,
Regurgitant Orifice Flow Rate Total of short and long view data, Effective Regurgitant
Orifice Area Total of short and long view data, Actual Flow Rate, and respective
Percentage Errors of each compared to the Actual Flow Rate.
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Figure 3.3.3: Correlation between calculated flow rates (Regurgitant Orifice Flow Rate)
and Actual Flow Rate in the short-view.

Figure 3.3.4: Correlation between calculated flow rates (Regurgitant Orifice Flow Rate)
and Actual Flow Rate in the long-view.
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Chapter Four: Discussion
4.1 Ex vivo Testing
During ex vivo testing, methods used regarding the steady flow and pulsatile flow
system were continuously improved, as well as testing methods regarding the use of the
Philips iE33 ultrasound machine and quantifying MR. A steady flow system proved to be
a practical preliminary practice in ex vivo testing, however, the MR jet was often difficult
to find when using Color Doppler as ultrasound machines are geared towards evaluating
pulsatile flows.
Throughout the test trials of the Full Cardiac Simulator, this pulsatile flow proved
to be noteworthy, clearly demonstrating its future potential. Although minimal data
regarding MR was obtained during these test trials, necessary modifications were made
and notable areas of improvements were found. The Full Cardiac Simulator shows the
possibilities of a more comprehensive ex vivo testing methodology that may be used not
only for the assessment of MR, but for the evaluating numerous cardiovascular diseases.

4.2 Computational Fluid Dynamics
PISA quantification is heavily dependent on the aliasing velocity (i.e. the color
shift shown in the simulated contours). This study considered the range of velocity
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magnitude in the plane of interest with a maximum of 1 m/s and a minimum of zero. 16
increments were set to the color map as this is also the case regarding Color Doppler and
Nyquist limit shifting with the Philips iE33 ultrasound machine. Shifting the baseline
aliasing velocity was practiced to more clearly view the PISA shell for an accurate
measurement of the radius. Specific coordinate planes were inserted through each valve
directly in the center of the short and long view of the orifice.
In all six cases evaluated, values obtained using the modified hemielliptic PISA
method consistently showed to underestimate the regurgitant flow in both the short and
long view of the orifice compared to the actual total regurgitant flow found at the
pulmonary veins. Furthermore, measurements taken in the long view continually showed
to underestimate regurgitant flow even more so than measurements take in the short view.
The percentage error shows to be greater than 30% in each view of every case, clearly
showing a substantial difference between the calculated and actual flow rate. In a clinical
setting, this would lead to an inaccurate diagnosis of MR severity, eventually leading to
improper treatment. Through computational simulations, improvements that can be made
in clinical measurement techniques were also displayed. Through being able to control
the anatomy and flow in these simulations, it can be shown where optimal transducer
placement may be in order to get the most accurate reading of PISA during TTE.
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4.3 Study Limitations & Future Works
4.3.1 Ex vivo Testing
Though the importance of having a full comprehensive cardiac simulator is
evident, there were certain impediments encountered when trying to measure MR. It is
prominent that all connection points of the simulator are secure as to ensure minimal
leakage. This is dependent on quality of materials, especially in regards to the porcine
heart used as a test subject. Ensuring this secure connection continued show difficulty at
the superior vena cava and pulmonary veins, as they were cut rather short by the source
which they were obtained from. Furthermore, cuts are often made on the heart itself by
these sources, indicating more areas for outflow. Apical connection could further be
improved by creating higher quality cannulas and using tubing at this connection that is
highly flexible, as to not put any strain on the heart and this connection point. Future
studies may also use a microscopic camera to insert into the pulmonary vein to evaluate
the condition and make necessary cuts on the mitral valve to enact MR without opening
the LA to do so.

4.3.2 Computational Fluid Dynamics
With PISA measurement accuracy being most prominent in MR quantification, it
continues to show the importance of the aliasing velocity setting during this time. With a
high aliasing velocity, PISA will be small; with a low aliasing velocity, PISA will be
large. (9) Aliasing velocity is based on the set Nyquist limit, which is equal to the pulse
repetition frequency (PRF)/2. In order to continue to evaluate PISA with the use of
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computational fluid dynamics, aliasing velocity and its implementation in a clinical
setting should continue to be further investigated. PISA and aliasing velocity may also be
further investigated through the use of fluid-structure interaction (FSI).
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Chapter Five: Conclusions
This study aimed to show the importance of further development in methods used
to quantify the severity of mitral regurgitation. Calculated flow rates throughout the
native mitral valve cases and the MitraClip mitral valve cases showed to underestimate
regurgitant flow in the short view of the orifice, and even further underestimate the flow
in the long view of the orifice compared to the actual regurgitant flow. Both native and
MitraClip cases of calculated flow rates in both views also correlated rather closely.
Computational simulations proved to be of significance in testing new mathematical
models and how they may further be executed in a clinical setting. Continuing to improve
clinical techniques used to obtain accurate measurements, mathematical models used for
quantification, computational fluid dynamic methods for patient specific simulations, and
the innovation of a Full Cardiac Simulator to advance ex vivo testing, exemplify the
many factors that need to be accounted for when attempting the quantify mitral
regurgitation as accurately as possible.
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Appendix A
Table A1: Phone call notes of discussions with Philips ultrasound technician on how to
improve ultrasound images.
Call

Date

#1

3/17/2021

Notes
•
•
•
•
•
•
•
•

#2

7/22/2021

•
•
•
•
•

We have x51 transducer
Steady flow may be difficult to test on
Particles may be problem for clear image; adds
density
Want transducer on LV
Contrast preset designed for infused bubbles;
keeps beam from bursting ultrasound bubbles
Low flow = want low Nyquist ; higher pressure
= increase Nyquist
Fluid added to RA/RV will help with imaging
Apical view on LV of patient
Better images in trial 7/19/2021
Depth is too deep; decrease this
Need to find 2D anatomy first before color
doppler
Transducer posterior to aortic valve for 4
chamber valve
Bring more posterior to better see MV

Table A2: Experimental testing notes taken throughout ex vivo testing.
Trial
Trial 1

Date
2/17/2021

Trial 2

2/24/2021

•
•
•
•

Notes
Put together flow system
Tested connection points
Tested connection of pig heart to flow
system
Practice with ultrasound machine; getting
familiar with settings and transducer
placement on the heart
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Trial 3

3/3/2021

•
•
•
•

Trial 4

3/7/2021

Trial 5

3/10/2021

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Trial 6

3/12/2021

•
•
•
•
•
•
•
•
•

Trial 7

3/18/2021

•
•
•
•

Pressure at 60mmhg at 5:22pm
Pressure at 75mmhg at 5:40pm
Pressure at 26mmhg at 6:12pm
Flow meter only worked once; read at 2.18
L/min
After image 11 cut more valve
Flow rate measured at 2.6 L/min
Flow rate measured at 5.4 L/min at 2:03pm
Too many particles were used
Pressure 48.7mmhg @ 12:13pm
Pressure 46.5mmhg @ 1:22pm
Pressure 40.1mmhg @ 1:33pm
Pressure 46.1mmhg at 10:19am
Pressure 43.4 at 10:24am
Pressure 46.6mmhg at 10:28am
Pressure at 45.4mmhg at 11:01am
Pressure at 45.4mmhg at 11:14am
Pressure at 50.6mmhg at 11:56am
Pressure at 44.1mmhg at 12:21pm
Pressure at 48.9mmhg at 12:25pm
Start with a small amount of PIV particles
Flow rate measured at 5.3 L/min
Photos 1-6; No changes were made from
Trial 2
Added more PIV particles half way through;
Cut more muscle
Flow rate measured at 9.4 L/min; Photos 717
Added more particles
Flow rate measured at 8.6 L/min; Photos 1822
Flow rate measured at 9.5 L/min; Photos 2339
Change in heart position; now in vertical
position
Flow rate measured at 9.01 L/min
Pressure 191mmhg at 3:45pm
Pressure 159mmhg at 3:55pm
Flow rate at 0.55 L/min at 3:45pm
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•
•
•
•
•
•
Trial 8

3/19/2021

Trial 9

3/20/2021

•
•
•
•
•
•
•
•

Trial 10

7/8/2021

Trial 11

7/19/2021

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Pressure 186mmhg at 3:45pm
Flow rate at 0.43 L/min at 3:55pm
Flow rate at 0.62 L/min at 4:15pm
Cutting 1 chordae at A2; suture
Can hear the jet flow difference
Aortic tear continued to get worse as time
went on
Pressure 118.7mmhg at 6:57pm
Pressure 130.3mmhg at 7:01pm
Flow rate at 0.75 L/min at 6:54pm
Flow rate at 0.63 L/min at 6:55pm
Flow rate at 0.78 L/min at 7:40pm
Flow rate measured at 1.21 L/min @
10:20am
Flow rate measured at 0.54 L/min @
10:22am
Flow rate measured at 1.25 L/min @
11:43am
Pressure 98mmhg @ 10:17 am
Pressure 63.1mmhg @ 10:23am
Pressure 91.2mmhg @ 11:43am
Pressure 138mmhg @ 11:57 am
Image 1 is without water sack
Image 32; used water sack for transducer
Test better transducer placement and Nyquist
baseline shift to accurately see PISA jet
Cut RV off
Cut LA appendage off; next time suture this
entirely
Septum thickness is roughly ½ inch thick;
along with around LV
Apex is roughly 1 inch thick
“X” cut on apex to insert cannula; inside
valve to create hole insertion
Cut MV through cannula insertion; mark at
commissure from pressurized top
Cut on P2; cut on A2 is better; made jet
halfway through leaflet
4cm down from top is pump jet
12cm down from top view is MV jet
70

Trial 12

8/13/2021

•
•
•
•
•
•
•
•
•
•
•
•

Trial 13

8/27/2021

•

•
•

Removal of RV to test transducer on LV
Need to pressure transducer tops
Need better stand for the system
Look at LVAD video and their cannulas
Create cannula with inner LV piece as well
Need fresh sheep or pig hearts; need to size
connections down to ½ inch
Need flexible tubing
Need to create “Y” piece for pump
connection
Need heart tray / stand system
Prep. hearts day before testing; with cuts and
connection pieces
Need heart to be cold
Need to be able to easily slide tubing on to
adapters
Biggest issue is connection at the pulmonary
veins; difficult with the multiple connections
and needing to suture; Sutures only holding
up for so long
Still need better cannulas
Need custom tubing that is very flexible and
does not put a pressure / strain on the
connection to the heart
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Figure A3: Full Cardiac Simulator. This image was used to help promote the work that
we are able to do “in-house”, using numerous machines within our machine shop.

72

